Sign up USA
Proactive Investors - Run By Investors For Investors

Sarepta soars on positive results from early-stage DMD clinical trial

The phase I/II study of Golodirsen hit all of its primary and secondary endpoints, with patients seeing a significant rise in dystrophin which is vital for muscle function
young boy
Duchenne muscular dystrophy is a rare muscle wasting disease that predominantly affects young boys

Shares in Sarepta Therapeutics Inc (NASDAQ:SRPT) surged in pre-market trade on Wednesday after the drug developer reported successful results from an early stage trial of its Duchenne muscular dystrophy treatment.

Sarepta said the phase I/II study of Golodirsen met all primary and secondary endpoints.

DMD is a rare progressive disease muscle disease found only in young boys who lack the protein dystrophin which is critical to muscle function.

All of the 25 boys who took part in the European trial responded to the treatment which Sarepta said demonstrated “proof of mechanism”.

On average, the levels of dystrophin in each patient increased almost eleven-fold from baseline.

Sarepta already has a drug that received accelerated approval from the FDA last year and is approved for treatment in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping.

That accounts for around 13% of the DMD market. Golodirsen is testing patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping, which accounts for around 8% of patients.

“This is now the second exon-skipping agent to have shown a statistically significant increase in dystrophin production, validating the exon-skipping approach to treating DMD boys with amenable mutations,” said principal investigator Francesco Muntoni.

Sarepta shares added 14.3% tin pre-market trading to US$46.94. In the regular session they added over 14% to $46.93 each.

View full SRPT profile View Profile

Sarepta Therapeutics Timeline

Related Articles

Workers at CERN
September 29 2017
The technology being developed is cheaper and smaller than the current units, which are almost prohibitively expensive
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
1507647205_biotech_517925923.jpg
October 10 2017
Last month the group revealed its Barocycler 2320EXTREME device had been selected as a finalist in the prestigious R&D 100 Awards for 2017.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use